

Deferred Registration - Quotient Sciences

Code: QSC303945

Submission date 13/08/2026	Recruitment status Recruiting	☒ Prospectively registered ☐ Protocol
Registration date 01/09/2026	Overall study status Deferred	☐ Statistical analysis plan ☐ Results
Last Edited 09/09/2026	Condition category Other	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)

Principal investigator

Contact name

Dr Sharan Sidhu

Contact details

Mere Way, Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 330 303 1000
recruitment@weneedyou.co.uk

Type(s)

Public, Scientific

Contact name

Mr Early Phase Clinical Team

Contact details

Sbarc | Spark, Maindy Road
Cardiff
United Kingdom
CF24 4HQ

+44 292 002 8450
info@draigtherapeutics.com

Additional identifiers

Integrated Research Application System (IRAS)
1014164

CRO study code
Quotient Sciences Code: QSC303945

Study information

Scientific Title
Quotient Sciences code: QSC303945 [Full scientific title to be added on or before the deferral expiry date]

Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 07/09/2026, London - Brent REC (Health Research Authority, 2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8115; brent.rec@hra.nhs.uk), ref: 26 /LO/0370

Primary study design
Interventional

Allocation
N/A: single arm study

Masking
Open (masking not used)

Control
Uncontrolled

Assignment
Single

Purpose
Phase 1 study in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

Completion date

16/11/2026

Eligibility

Key inclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed

Yes

Age group

Mixed

Lower age limit

30 Years

Upper age limit

65 Years

Sex

Male

Total final enrolment

0

Key exclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment

25/09/2026

Date of final enrolment

16/11/2026

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Quotient Sciences Limited

Mere Way, Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

Sponsor information**Organisation**

Draig Therapeutics Ltd.

Funder(s)**Funder type****Funder Name**

Draig Therapeutics Ltd.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available